Bifunctional Compounds Degrade BTK via Ubiquitin Ligase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B-cell malignancies and autoimmune/inflammatory diseases, such as those targeting Bruton's tyrosine kinase (BTK), face limitations, particularly with resistance to inhibitors like ibrutinib and the need for novel mechanisms beyond stoichiometric inhibition.
Innovation Solution
Development of bifunctional compounds that induce proteolytic degradation of BTK through recruitment to a ubiquitin ligase, specifically enhancing Immunomodulatory imide Drug (IMiD) activity, allowing for targeted degradation of BTK and associated proteins like Aiolos and Ikaros, effectively blocking B-cell signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stoichiometric inhibition using ibrutinib is used to target BTK, then BTK kinase activity is blocked, but resistance develops and the mechanism becomes less effective over time
Solution Approach 1:
The patent changes the mechanism from stoichiometric inhibition to proteolytic degradation. Instead of blocking BTK kinase activity reversibly or irreversibly, the compound promotes ubiquitin-mediated proteasomal degradation of BTK, fundamentally altering how BTK is targeted and eliminating the resistance mechanism that arises with repeated inhibition exposure.
Solution Approach 2:
The invention extracts and removes BTK protein from the cell through targeted degradation. By using a heterobifunctional compound that recruits BTK to the ubiquitin ligase complex, the approach completely eliminates BTK protein rather than merely inhibiting its activity, providing a more durable and reliable therapeutic effect.
2Reliability
If heterobifunctional compounds are used to recruit BTK to ubiquitin ligase for degradation, then BTK protein is completely removed, but the compound structure and mechanism become more complex
Solution Approach 1:
The heterobifunctional compound performs multiple functions: it binds to the E3 ubiquitin ligase CRBN, recruits BTK as a substrate, and triggers proteasomal degradation. This multi-functional approach achieves complete BTK removal through a single molecular mechanism, balancing structural complexity with therapeutic effectiveness.
3Adaptability or versatility
If IMiD activity is enhanced in the bifunctional compound, then additional immune modulation is achieved, but the compound design and potential side effects increase
Solution Approach 1:
The patent merges two therapeutic activities into a single compound: BTK degradation through CRBN recruitment and IMiD-mediated immune modulation. The compound simultaneously degrades BTK and exhibits IMiD activity, providing dual mechanism of action that enhances versatility while managing complexity through integrated design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate enhanced IMiD activity, effectively degrading BTK and associated proteins, providing potent anti-tumor activity and overcoming resistance to existing BTK inhibitors, thus offering a new therapeutic approach for B-cell malignancies and autoimmune diseases.
Implementation Method 1
proteolytic degradation of BTK
Implementation Method 2
recruit BTK to a ubiquitin ligase thus promoting ubiquitylation and proteasomal degradation of BTK
Implementation Method 3
Through binding to CRBN, IMiDs alter the substrate repertoire of the CRBN ubiquitin ligase complex
Data Source
AI summary
This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway with enhanced IMiD activity. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.